Please ensure Javascript is enabled for purposes of website accessibility

Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials

By Brian Orelli, PhD – Apr 20, 2020 at 4:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In combination with other drugs, Opdivo helped patients with kidney cancer and mesothelioma.

Bristol Myers Squibb (BMY -0.86%) started off the week by delivering a double-dose of good news regarding its cancer drug Opdivo: In two late-stage clinical trials testing the drug in patients with kidney cancer and mesothelioma, it met its primary endpoints.

In the CheckMate-9ER clinical trial, the combination of Opdivo and Exelixis' (EXEL -1.01%) Cabometyx improved progression-free survival -- the time it takes for the tumor to start growing again while the patient remains alive -- compared to Pfizer's (PFE -0.91%) Sutent in previously untreated kidney cancer patients. The combination also improved overall survival and had a higher response rate than Sutent. The companies are saving the full results to release at an upcoming medical conference, so investors will have to wait to see the exact extent of the improvement over Sutent.

Opdivo is already approved for use in combination with Bristol Myers Squibb's Yervoy in patients with previously untreated kidney cancer, so the results are a bigger deal for Exelixis than the larger pharmaceutical company. Shares of Exelixis closed trading Monday up more than 21% Monday, while Bristol Myers was up 1.8%. The broad market S&P 500 index, by contrast, was down by 1.8%. 

Doctor showing a report to a patient in a hospital bed

Image source: Getty Images.

In the mesothelioma trial, CheckMate-743, Opdivo plus Yervoy improved overall survival compared to standard chemotherapy. And here too, Bristol Myers is saving the data to be released at an upcoming medical meeting.

Opdivo is approved by the Food and Drug Administration to treat 11 different types of cancer. The drug works by blocking a protein called programmed death receptor-1 (PD-1) on immune cells that tumor cells use to signal to the immune cells that they shouldn't be attacked. By blocking PD-1, Opdivo allows the immune system to attack the tumor.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Exelixis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$71.09 (-0.86%) $0.62
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40
Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$15.68 (-1.01%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.